Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 57.50
+1.60 (2.86%)
Jun 18, 2026, 4:08 PM HKT
Keymed Biosciences Market Cap
Keymed Biosciences has a market cap or net worth of 16.94 billion as of June 18, 2026. Its market cap has increased by 52.90% in one year.
Market Cap
16.94B
Enterprise Value
15.68B
Revenue
797.12M
Ranking
n/a
PE Ratio
n/a
Stock Price
57.50
Market Cap Chart
Since July 8, 2021, Keymed Biosciences's market cap has decreased from 18.43B to 16.94B, a decrease of -8.08%. That is a compound annual growth rate of -1.69%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 18, 2026 | 16.94B | 7.58% |
| Dec 31, 2025 | 15.75B | 84.90% |
| Dec 31, 2024 | 8.52B | -37.32% |
| Dec 29, 2023 | 13.59B | -4.15% |
| Dec 30, 2022 | 14.17B | 46.87% |
| Dec 31, 2021 | 9.65B | -47.63% |
| Jul 8, 2021 | 18.43B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genscript Biotech | 25.12B |
| InnoCare Pharma | 22.31B |
| Metis TechBio | 16.60B |
| Duality Biotherapeutics | 16.42B |
| Zai Lab | 15.61B |
| TenNor Therapeutics (Suzhou) | 13.15B |
| TransThera Sciences (Nanjing) | 12.19B |
| Ascentage Pharma Group International | 12.18B |